DE602004031681D1 - Multifunktionelle Cytokine - Google Patents
Multifunktionelle CytokineInfo
- Publication number
- DE602004031681D1 DE602004031681D1 DE602004031681T DE602004031681T DE602004031681D1 DE 602004031681 D1 DE602004031681 D1 DE 602004031681D1 DE 602004031681 T DE602004031681 T DE 602004031681T DE 602004031681 T DE602004031681 T DE 602004031681T DE 602004031681 D1 DE602004031681 D1 DE 602004031681D1
- Authority
- DE
- Germany
- Prior art keywords
- present
- nucleic acid
- acid molecule
- fusion protein
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5418—IL-7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Wood Science & Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03360086 | 2003-07-21 | ||
US53932004P | 2004-01-28 | 2004-01-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602004031681D1 true DE602004031681D1 (de) | 2011-04-14 |
Family
ID=43734828
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602004031681T Active DE602004031681D1 (de) | 2003-07-21 | 2004-07-20 | Multifunktionelle Cytokine |
Country Status (10)
Country | Link |
---|---|
US (2) | US7534585B2 (de) |
EP (3) | EP1944318B1 (de) |
JP (1) | JP4842128B2 (de) |
AT (2) | ATE500267T1 (de) |
AU (1) | AU2004263274B2 (de) |
CA (2) | CA2531773A1 (de) |
DE (1) | DE602004031681D1 (de) |
DK (2) | DK1648931T3 (de) |
ES (2) | ES2356154T3 (de) |
WO (1) | WO2005014642A2 (de) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7968684B2 (en) | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
WO2007121893A1 (en) * | 2006-04-21 | 2007-11-01 | Transgene S.A. | Method for treating hpv infected patients |
WO2008051220A1 (en) * | 2006-10-24 | 2008-05-02 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Interaction of il-27 and il-2 for treatment of tumors |
US8603950B2 (en) | 2007-02-20 | 2013-12-10 | Anaptysbio, Inc. | Methods of generating libraries and uses thereof |
WO2009152610A1 (en) * | 2008-06-20 | 2009-12-23 | The Royal Institution For The Advancement Of Learning/Mcgill University | Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof |
JP5757942B2 (ja) * | 2009-06-10 | 2015-08-05 | スティーヴン サニグ リサーチ インスティテュート リミテッド.Stephen Sanig Research Institute Ltd. | 表現型の可塑性を示す細胞を生成する方法 |
AU2010280981B2 (en) * | 2009-08-05 | 2016-01-28 | Nexigen Gmbh | Human HCV-interacting proteins and methods of use |
JP5897464B2 (ja) | 2009-08-07 | 2016-03-30 | トランジェーヌ、ソシエテ、アノニムTransgene S.A. | Hbv感染を治療するための組成物 |
WO2015089217A2 (en) | 2013-12-10 | 2015-06-18 | Bionz, Llc | Methods of developing selective peptide antagonists |
EP3636274A1 (de) | 2011-01-18 | 2020-04-15 | Bioniz, LLC | Zusammensetzungen und verfahren zur modulierung einer gamma-c-zytokin-aktivität |
KR20120093002A (ko) * | 2011-02-14 | 2012-08-22 | (주)에이티젠 | Nk 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트 |
WO2013074489A1 (en) | 2011-11-14 | 2013-05-23 | Emory University | Conjugates of gm-csf and il-7, compositions and methods related thereto |
US9840545B2 (en) | 2013-09-20 | 2017-12-12 | University Of Virginia Patent Foundation | Fusion protein comprising interleukin-2 and interleukin-33 |
NZ728175A (en) | 2014-08-11 | 2023-03-31 | Delinia Inc | Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases |
PL3359556T3 (pl) | 2015-10-09 | 2021-11-22 | Bioniz, Llc | Modulowanie aktywności gamma-c-cytokin |
CL2015003242A1 (es) * | 2015-11-04 | 2016-10-14 | Univ Chile | Virus aav/upr-plus, proteína de fusión upr-plus, método de tratamiento genético y su uso en el tratamiento enfermedades neurodegenerativas, tales como las enfermedades de parkinson y huntington, entre otras. |
US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
EP3453401A4 (de) * | 2016-05-06 | 2020-01-29 | Wang, Mulin | Interleukin-kombination und deren verwendung |
SG11201903302UA (en) | 2016-10-14 | 2019-05-30 | Xencor Inc | Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments |
AU2017359172A1 (en) | 2016-11-08 | 2019-05-16 | Delinia, Inc. | IL-2 variants for the treatment of autoimmune diseases |
EP3596108A4 (de) | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | Gezielte immuntoleranz |
US20210260162A1 (en) * | 2017-03-31 | 2021-08-26 | The Board Of Trustees Of The Leland Stanford Junior University | Synthekine compositions and methods of use |
JP2020521452A (ja) | 2017-05-24 | 2020-07-27 | パンディオン・セラピューティクス・インコーポレイテッド | 標的化免疫寛容 |
CA3080492A1 (en) * | 2017-09-06 | 2019-03-14 | Yale University | Interleukin-18 variants and methods of use |
US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
AU2019218785A1 (en) * | 2018-02-09 | 2020-09-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Tethered interleukin-15 and interleukin-21 |
EP3765069A1 (de) | 2018-03-16 | 2021-01-20 | Zoetis Services LLC | Peptid-vakzine gegen interleukin-31 |
CN112437777A (zh) | 2018-04-18 | 2021-03-02 | Xencor股份有限公司 | 包含IL-15/IL-15RA Fc融合蛋白和TIM-3抗原结合结构域的靶向TIM-3的异源二聚体融合蛋白 |
US11524991B2 (en) | 2018-04-18 | 2022-12-13 | Xencor, Inc. | PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof |
JP2022504550A (ja) | 2018-10-12 | 2022-01-13 | ゼンコア インコーポレイテッド | Pd-1標的化il-15/il-15rアルファfc融合タンパク質およびその組み合わせ療法での使用 |
EP3897853A1 (de) | 2018-12-20 | 2021-10-27 | Xencor, Inc. | Zielgerichtete heterodimere fc-fusionsproteine mit il-15/il-15ra und nkg2d-antigenbindenden domänen |
JP2022533702A (ja) | 2019-05-20 | 2022-07-25 | パンディオン・オペレーションズ・インコーポレイテッド | MAdCAM標的化免疫寛容 |
TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
KR20220110209A (ko) * | 2019-11-05 | 2022-08-05 | 메디카인 인코포레이티드 | 이중 il-2r 및 il-7r 결합 화합물 |
US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
WO2022045849A1 (ko) * | 2020-08-31 | 2022-03-03 | 주식회사 지아이셀 | Il15 단백질, il15 수용체 알파 단백질, fc 도메인 및 il2 단백질을 포함하는 융합단백질 및 이의 용도 |
WO2023161853A1 (en) | 2022-02-23 | 2023-08-31 | Bright Peak Therapeutics Ag | Activatable il-18 polypeptides |
Family Cites Families (115)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4711955A (en) | 1981-04-17 | 1987-12-08 | Yale University | Modified nucleotides and methods of preparing and using same |
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
CA1223831A (en) | 1982-06-23 | 1987-07-07 | Dean Engelhardt | Modified nucleotides, methods of preparing and utilizing and compositions containing the same |
EP0125914B1 (de) | 1983-05-13 | 1992-04-01 | Kabushiki Kaisha Toshiba | Paneel für freien Zugang zu Signalkabel und Energiekabel |
US5082658A (en) | 1984-01-16 | 1992-01-21 | Genentech, Inc. | Gamma interferon-interleukin-2 synergism |
WO1985004420A1 (en) * | 1984-03-29 | 1985-10-10 | Takeda Chemical Industries, Ltd. | Novel dna and its use |
EP0158198A1 (de) * | 1984-03-29 | 1985-10-16 | Takeda Chemical Industries, Ltd. | DNA und ihre Verwendung |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
FI861417A0 (fi) | 1985-04-15 | 1986-04-01 | Endotronics Inc | Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav. |
FR2583429B1 (fr) | 1985-06-18 | 1989-11-03 | Transgene Sa | Vecteur d'expression de l'interferon u dans les cellules de mammifere, procede pour sa mise en oeuvre et produit obtenu et composition pharmaceutique contenant l'interferon u |
US4935233A (en) * | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
DE3712985A1 (de) * | 1987-04-16 | 1988-11-03 | Hoechst Ag | Bifunktionelle proteine |
US5359035A (en) | 1985-12-21 | 1994-10-25 | Hoechst Aktiengesellschaft | Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF) |
FR2606029B2 (fr) | 1986-04-08 | 1989-02-03 | Transgene Sa | Vecteur viral et adn recombinant codant pour une glycoproteine du virus agent causal du s.i.d.a., culture cellulaire infectee par ce vecteur, procede de preparation de la glycoproteine, glycoproteine obtenue, vaccin et anticorps obtenus |
FR2643817B1 (fr) | 1989-03-06 | 1993-12-17 | Transgene Sa | Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus |
EP1088830A3 (de) | 1987-06-22 | 2004-04-07 | Medeva Holdings B.V. | Partikel von Hepatitis B Oberflächenantigen |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
FR2632863B2 (fr) | 1987-10-29 | 1990-08-31 | Transgene Sa | Virus du fowlpox recombinant et vaccins derives de ces virus |
US5662896A (en) * | 1988-03-21 | 1997-09-02 | Chiron Viagene, Inc. | Compositions and methods for cancer immunotherapy |
GB8819209D0 (en) | 1988-08-12 | 1988-09-14 | Research Corp Ltd | Polypeptide & dna encoding same |
CA2018273C (en) | 1989-06-09 | 1999-04-06 | Peter D. Senter | Thermally stable cytosine deaminase |
DE69031556T2 (de) | 1989-07-25 | 1998-05-14 | Smithkline Beecham Biolog | Antigene sowie Verfahren zu deren Herstellung |
FR2650838A1 (fr) | 1989-08-09 | 1991-02-15 | Transgene Sa | Vecteurs d'expression du facteur ix dans une cellule eucaryote superieure, procede de preparation de facteur ix par des animaux transgeniques et facteur ix obtenu |
US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
WO1992004455A1 (en) | 1990-08-29 | 1992-03-19 | Genetics Institute, Inc. | Multidomain hematopoiesis stimulators |
FR2668064B1 (fr) | 1990-10-23 | 1994-12-16 | Transgene Sa | Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne. |
GB9105383D0 (en) | 1991-03-14 | 1991-05-01 | Immunology Ltd | An immunotherapeutic for cervical cancer |
US5358866A (en) | 1991-07-03 | 1994-10-25 | The United States Of America As Represented By The Department Of Health And Human Services | Cytosine deaminase negative selection system for gene transfer techniques and therapies |
DK0595935T3 (da) | 1991-07-19 | 2003-07-21 | Csl Ltd | Papillomavirusvaccine |
KR100251505B1 (ko) | 1991-11-16 | 2000-05-01 | 장 스테판느 | 말라리아원충으로부터의 cs 및 hbsag 사이의 혼성 단백질(hybrid protein between cs from plasmodium and hbsag) |
US5229109A (en) | 1992-04-14 | 1993-07-20 | Board Of Regents, The University Of Texas System | Low toxicity interleukin-2 analogues for use in immunotherapy |
DE122007000097I1 (de) | 1992-06-25 | 2008-03-27 | Papillomavirus vakzine | |
US5786148A (en) | 1996-11-05 | 1998-07-28 | Incyte Pharmaceuticals, Inc. | Polynucleotides encoding a novel prostate-specific kallikrein |
GB9223084D0 (en) | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
EP0905253A3 (de) | 1992-12-03 | 2000-11-02 | Genzyme Corporation | Von allen E4-ORF ausgenommen ORF6 deletierte Adenovirus-Vector |
US5747323A (en) | 1992-12-31 | 1998-05-05 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Retroviral vectors comprising a VL30-derived psi region |
US5581476A (en) | 1993-01-28 | 1996-12-03 | Amgen Inc. | Computer-based methods and articles of manufacture for preparing G-CSF analogs |
US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
ATE492289T1 (de) | 1993-03-09 | 2011-01-15 | Univ Rochester | Herstellung von menschlichen papillomavirus hbv- 11 kapsidprotein l1 und virus-ähnliche partikeln |
US6133028A (en) | 1993-05-28 | 2000-10-17 | Transgene S.A. | Defective adenoviruses and corresponding complementation lines |
FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
FR2707091B1 (fr) | 1993-06-30 | 1997-04-04 | Cohen Haguenauer Odile | Vecteur rétroviral pour le transfert et l'expression de gènes dans des cellules eucaryotes. |
FR2711523B1 (fr) | 1993-10-26 | 1996-02-16 | Transgene Sa | Procédé de préparation d'un aérosol viral. |
US5698443A (en) | 1995-06-27 | 1997-12-16 | Calydon, Inc. | Tissue specific viral vectors |
US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
EP0760861A1 (de) | 1994-05-20 | 1997-03-12 | The Board Of Trustees Of The Leland Stanford Junior University | Selbststandiges replikationsystem fur zellen von saugetieren |
US6638762B1 (en) | 1994-11-28 | 2003-10-28 | Genetic Therapy, Inc. | Tissue-vectors specific replication and gene expression |
US5998205A (en) | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
FR2727689A1 (fr) | 1994-12-01 | 1996-06-07 | Transgene Sa | Nouveau procede de preparation d'un vecteur viral |
FR2730735B1 (fr) | 1995-02-20 | 1997-05-09 | Pasteur Institut | Sequences amplificatrices, vecteurs portant ces sequences et leurs utilisations dans des compositions pour l'expression de sequences nucleotidiques dans des cellules transfectees, applications therapeutiques et vaccinales |
US5837520A (en) | 1995-03-07 | 1998-11-17 | Canji, Inc. | Method of purification of viral vectors |
US5759776A (en) | 1995-06-05 | 1998-06-02 | California Pacific Medical Center | Targets for breast cancer diagnosis and treatment |
AU705035B2 (en) | 1995-06-07 | 1999-05-13 | Baylor College Of Medicine | Nucleic acid transporters for delivery of nucleic acids into a cell |
UA68327C2 (en) | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
FR2737222B1 (fr) | 1995-07-24 | 1997-10-17 | Transgene Sa | Nouveaux vecteurs viraux et lignee pour la therapie genique |
US6090618A (en) | 1996-10-07 | 2000-07-18 | Arch Development Corporation | DNA constructs and viral vectors comprising a smooth muscle promoter |
WO1998008947A1 (en) * | 1995-12-19 | 1998-03-05 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Enhancement of dna immunization through the use of cytokines |
EP0816510A4 (de) | 1995-12-22 | 2001-04-11 | Toray Industries | Verfahren zur herstellung von biologisch aktiven, fusionierten proteinen |
FR2746815A1 (fr) | 1996-03-26 | 1997-10-03 | Pasteur Institut | Sequences en amont du gene sm 22, vecteurs les contenant et leurs utilisations therapeutiques, notamment dans le traitement des maladies vasculaires |
US5776683A (en) | 1996-07-11 | 1998-07-07 | California Pacific Medical Center | Methods for identifying genes amplified in cancer cells |
WO1998000524A1 (fr) | 1996-07-01 | 1998-01-08 | Rhone-Poulenc Rorer S.A. | Procede de production d'adenovirus recombinants |
US5883320A (en) | 1996-07-15 | 1999-03-16 | Emmons Guitar Company, Inc. | Pedal guitar |
EP0931158A1 (de) | 1996-09-06 | 1999-07-28 | The Trustees Of The University Of Pennsylvania | Indutierbare methode zur herstellung von rekombinanten adeno-assoziierten viren mittels t7 polymerase |
US5955306A (en) | 1996-09-17 | 1999-09-21 | Millenium Pharmaceuticals, Inc. | Genes encoding proteins that interact with the tub protein |
US5994132A (en) | 1996-10-23 | 1999-11-30 | University Of Michigan | Adenovirus vectors |
EP0968284B1 (de) | 1996-11-20 | 2006-12-13 | Introgen Therapeutics, Inc. | Ein verbessertes verfahren zur produktion und reinigung von adenoviralen vektoren |
DE69739961D1 (de) | 1996-12-13 | 2010-09-23 | Schering Corp | Methoden zur Virus-Reinigung |
DK1273304T4 (da) | 1997-02-21 | 2009-08-31 | Amgen Inc | Anvendelse af interleukin-15 |
US5998598A (en) | 1997-03-10 | 1999-12-07 | The United States Of America, As Represented By The Department Of Health And Human Services | Immunoadhesins and methods of production and use thereof |
DE19823351A1 (de) * | 1997-05-16 | 1998-12-10 | Krause Hans | Mittel zur Verhinderung der Zellapoptose bei Krankheiten |
US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
FR2763958A1 (fr) | 1997-05-29 | 1998-12-04 | Transgene Sa | Produit de combinaison associant un acide nucleique a une substance desorganisant la matrice extracellulaire pour la therapie genique |
FR2763959A1 (fr) | 1997-06-02 | 1998-12-04 | Transgene Sa | Nouveaux vecteurs adenoviraux recombinants comprenant une sequence d'epissage |
EP0988053A1 (de) | 1997-06-11 | 2000-03-29 | Aquila Biopharmaceuticals, Inc. | Gereinigte saponinen als orale adjuvantien |
DE69738316T2 (de) | 1997-06-20 | 2008-09-25 | Mirus Bio Corp., Madison | Verfahren zur verabreichung eines polynukleotids über das gefä system |
AU707186B2 (en) | 1997-07-01 | 1999-07-01 | Transgene S.A. | Compositions useful for transferring therapeutically active substances into a target cell, and their use in gene therapy |
FR2766091A1 (fr) | 1997-07-18 | 1999-01-22 | Transgene Sa | Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee |
JP3142511B2 (ja) * | 1997-11-05 | 2001-03-07 | イビデン株式会社 | 無電解メッキ用接着剤およびその製造方法 |
WO1999027113A1 (en) | 1997-11-26 | 1999-06-03 | Geron Corporation | Mouse telomerase reverse transcriptase |
AU756828B2 (en) | 1997-12-02 | 2003-01-23 | Powderject Vaccines, Inc. | Transdermal delivery of particulate vaccine compositions |
GB9800927D0 (en) | 1998-01-16 | 1998-03-11 | Univ Bristol | Recombinant adenoviral delivery of antibody fusion proteins |
DK1659179T3 (da) | 1998-02-05 | 2011-10-10 | Glaxosmithkline Biolog Sa | Tumor-associerede antigenderivater fra MAGE-familien og nucleinsyresekvenser kodende for dem anvendt til fremstilling af fusionsproteiner og sammensætninger til vaccination |
AU3560399A (en) | 1998-04-15 | 1999-11-01 | Ludwig Institute For Cancer Research | Tumor associated nucleic acids and uses therefor |
FR2777570A1 (fr) | 1998-04-17 | 1999-10-22 | Transgene Sa | Mutant ayant une activite phosphoribosyl transferase |
JP2002513775A (ja) | 1998-05-06 | 2002-05-14 | トランジェーヌ、ソシエテ、アノニム | 細胞の中へのポリヌクレオチドのトランスフェクションを改良する治療組成物を調製するためのヌクレアーゼインヒビターまたはインターロイキン−10(il−10)の使用、および遺伝子治療に有用な組成物 |
DZ2788A1 (fr) * | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
JP3864610B2 (ja) | 1998-05-21 | 2007-01-10 | 旭硝子株式会社 | 水分散型撥水撥油剤組成物およびその製造方法 |
EP1199368B1 (de) | 1998-07-07 | 2004-01-21 | Transgene S.A. | Verwendung der Leserahmen der adenoviralen E4-Region zur Verbesserung der Genexpression |
KR20010083111A (ko) | 1998-07-14 | 2001-08-31 | 길리스 스티브 | 전립선암의 치료 및 진단을 위한 조성물 및 방법 |
FR2782732A1 (fr) | 1998-08-28 | 2000-03-03 | Transgene Sa | Systeme d'expression inductible |
US6900049B2 (en) | 1998-09-10 | 2005-05-31 | Cell Genesys, Inc. | Adenovirus vectors containing cell status-specific response elements and methods of use thereof |
US6552005B1 (en) * | 1998-09-29 | 2003-04-22 | Uab Research Foundation | Molecular chemotherapy enhancement of radiotherapy |
EP0998945A1 (de) | 1998-09-30 | 2000-05-10 | Transgene S.A. | Verwendung von Magnesium (Mg2+) zur Erhöhung der Gen-Verabreichung bei Gentherapie |
FR2787465A1 (fr) | 1998-12-21 | 2000-06-23 | Transgene Sa | Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes |
CN1195057C (zh) | 1998-12-31 | 2005-03-30 | 森泰莱昂公司 | 分离病毒颗粒的方法 |
EP1147181B1 (de) | 1999-02-04 | 2004-05-12 | Geron Corporation | Replikativer virus gesteuert von dem promotor der reversen telomerase transkriptase zur behandlung von krebs |
US7264958B1 (en) | 1999-02-22 | 2007-09-04 | Transgene, S.A. | Method for obtaining a purified viral preparation |
HU229148B1 (en) * | 1999-03-09 | 2013-09-30 | Zymogenetics Inc Seattle | Human cytokine as ligand of the zalpha receptor and uses thereof |
US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
CA2380331C (en) * | 1999-08-09 | 2012-11-20 | Lexigen Pharmaceuticals Corp. | Multiple cytokine-antibody complexes |
CA2380537C (en) | 1999-11-15 | 2011-01-18 | Onyx Pharmaceuticals, Inc. | An oncolytic adenovirus |
JP2003518511A (ja) | 1999-12-28 | 2003-06-10 | トランジェーヌ、ソシエテ、アノニム | ポリヌクレオチドを細胞へトランスフェクションするための組成物を調製するためのリチウム(Li+)の使用および遺伝子治療で有用な組成物 |
AU2001245414A1 (en) | 2000-03-10 | 2001-09-24 | The Board Of Trustees Of Leland Stanford Junior University | Treatment of allergies |
CA2341356C (en) | 2000-04-14 | 2011-10-11 | Transgene S.A. | Poxvirus with targeted infection specificity |
NZ523123A (en) * | 2000-06-02 | 2005-12-23 | Smithkline Beecham Corp | Methods of treating viral diseases with IL-18 and IL-18 combinations with anti-viral drugs |
EP1349873B1 (de) | 2000-09-14 | 2009-04-01 | Beth Israel Deaconess Medical Center, Inc. | Modulierung von il-2 und il-15 vermittelten t zellantworten |
WO2002053760A2 (en) | 2000-12-18 | 2002-07-11 | Geron Corporation | Chimeric cytolytic viruses for cancer treatment |
WO2002063044A2 (en) | 2001-02-08 | 2002-08-15 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the il15 gene |
DE60208692T2 (de) | 2001-03-08 | 2006-07-13 | Ares Trading S.A. | Interleukin -18 mutantenproteine, deren herstellung und verwendung |
WO2002096939A2 (en) | 2001-05-30 | 2002-12-05 | Transgene S.A. | Adenovirus protein ix, its domains involved in capsid assembly, transcriptional activity and nuclear reorganization |
WO2002102404A1 (en) * | 2001-06-18 | 2002-12-27 | Institut National De La Recherche Agronomique | Uses of cytokines |
CA2471532A1 (en) * | 2001-10-23 | 2003-05-01 | Centre For Translational Research In Cancer | A synthetic chimeric fusion protein with immuno-therapeutic uses |
EP1310561A1 (de) | 2001-11-09 | 2003-05-14 | Transgene S.A. | Chimäre Promotoren zur Kontrolle der Expression in Skelettmuskelzellen |
EP1454138B1 (de) | 2001-12-04 | 2012-01-18 | Merck Patent GmbH | Immunocytokine mit modulierter selektivität |
WO2004007537A2 (en) | 2002-07-10 | 2004-01-22 | Transgene S.A. | Modified adenoviral fiber with ablated to cellular receptors |
-
2004
- 2004-07-20 CA CA002531773A patent/CA2531773A1/en not_active Abandoned
- 2004-07-20 DK DK04763359.9T patent/DK1648931T3/da active
- 2004-07-20 AU AU2004263274A patent/AU2004263274B2/en not_active Ceased
- 2004-07-20 EP EP08152608A patent/EP1944318B1/de not_active Not-in-force
- 2004-07-20 DE DE602004031681T patent/DE602004031681D1/de active Active
- 2004-07-20 AT AT08152608T patent/ATE500267T1/de active
- 2004-07-20 CA CA002678736A patent/CA2678736A1/en not_active Abandoned
- 2004-07-20 ES ES04763359T patent/ES2356154T3/es active Active
- 2004-07-20 EP EP08152603A patent/EP1925626A1/de not_active Withdrawn
- 2004-07-20 JP JP2006520780A patent/JP4842128B2/ja not_active Expired - Fee Related
- 2004-07-20 AT AT04763359T patent/ATE497974T1/de active
- 2004-07-20 DK DK08152608.9T patent/DK1944318T3/da active
- 2004-07-20 WO PCT/EP2004/008114 patent/WO2005014642A2/en active Application Filing
- 2004-07-20 EP EP04763359A patent/EP1648931B1/de not_active Not-in-force
- 2004-07-20 ES ES08152608T patent/ES2359473T3/es active Active
- 2004-07-20 US US10/565,371 patent/US7534585B2/en not_active Expired - Fee Related
-
2009
- 2009-04-27 US US12/430,723 patent/US7947288B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1648931B1 (de) | 2011-02-09 |
US20070110713A1 (en) | 2007-05-17 |
ATE497974T1 (de) | 2011-02-15 |
JP2007523622A (ja) | 2007-08-23 |
CA2678736A1 (en) | 2005-02-17 |
JP4842128B2 (ja) | 2011-12-21 |
EP1944318A1 (de) | 2008-07-16 |
EP1925626A1 (de) | 2008-05-28 |
DK1944318T3 (da) | 2011-06-14 |
ES2359473T3 (es) | 2011-05-23 |
AU2004263274A1 (en) | 2005-02-17 |
WO2005014642A3 (en) | 2005-05-26 |
EP1944318B1 (de) | 2011-03-02 |
US7947288B2 (en) | 2011-05-24 |
EP1648931A2 (de) | 2006-04-26 |
CA2531773A1 (en) | 2005-02-17 |
ES2356154T3 (es) | 2011-04-05 |
DK1648931T3 (da) | 2011-03-07 |
WO2005014642A2 (en) | 2005-02-17 |
AU2004263274B2 (en) | 2009-11-05 |
ATE500267T1 (de) | 2011-03-15 |
US20100196324A1 (en) | 2010-08-05 |
US7534585B2 (en) | 2009-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602004031681D1 (de) | Multifunktionelle Cytokine | |
ATE454393T1 (de) | Egvii-endoglucanase und dafür codierende nukleinsäuren | |
WO2004048592A3 (en) | Bgl7 beta-glucosidase and nucleic acids encoding the same | |
WO2003052118A3 (en) | Bgl4 beta-glucosidase and nucleic acids encoding the same | |
WO2003052055A3 (en) | Egvii endoglucanase and nucleic acids encoding the same | |
CY1110868T1 (el) | Ελαχιστη αλληλουχια dna που δρα ως μονωτης της χρωματινης και η χρηση της στην πρωτεϊνικη εκφραση | |
WO2003052057A3 (en) | Egvi endoglucanase and nucleic acids encoding the same | |
WO2005003296A3 (en) | Albumin fusion proteins | |
DK1294876T3 (da) | EV-VEGF-nukleinsyrer og -polypeptider samt fremgangsmåder til deres benyttelse | |
ATE478955T1 (de) | Für antigene polypeptide des hiv type c kodierende nukleinsäuren, entsprechende polypeptide und verwendungen davon | |
EP1365025A4 (de) | Agarase und gen dafür | |
ATE263836T1 (de) | Chimere proteine, welche borrelia polypeptide beinhalten, verwendungen dafür | |
EP1481061A4 (de) | Gegen denaturierungsmittel stabile und/oder proteaseresistente, chaperonähnliche oligomere proteine, diese kodierende polynukleotide sowie ihre verwendungen | |
WO2004022697A3 (en) | Denaturat stable and/or protease resistant, chaperone-like oligomeric proteins, polynucleotides encoding same, their uses and methods of increasing a specific activity thereof | |
DE60220621D1 (de) | Posh Nukleinsäure, Polypeptide und darauf bezogene Verfahren | |
WO2002085922A3 (en) | Proteins and nucleic acids encoding same | |
WO2002090500A3 (en) | Novel human proteins, polynucleotides encoding them and methods of using the same | |
WO2002046408A3 (en) | Human proteins, polynucleotides encoding them and methods of using the same | |
ATE426033T1 (de) | Promoter sequenzen aus moos und dessen verwendung | |
DE602004021922D1 (de) | Induktion der blütenbildung | |
ATE547427T1 (de) | Verfahren zur rekombinanten herstellung von ribonukleoproteinen | |
WO2021231549A3 (en) | Engineered gene-editing proteins | |
DE60117641D1 (de) | Modulierte sekretierte alkalische Phosphatase (SEAP) Reporter Gene und Polypeptide | |
WO2004013281A3 (en) | Novel proteins and their uses |